OCX

ONCOCYTE
AMEX

Real-time Quotes | Nasdaq Last Sale

2.760
+0.130
+4.94%
Closed 16:00 05/29 EDT
OPEN
2.590
PREV CLOSE
2.630
HIGH
2.820
LOW
2.585
VOLUME
196.80K
TURNOVER
--
52 WEEK HIGH
4.330
52 WEEK LOW
1.500
MARKET CAP
185.52M
P/E (TTM)
-5.8008
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OCX stock price target is 6.23 with a high estimate of 7.75 and a low estimate of 5.00.

EPS

OCX News

More
Oncocyte Announces New Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrating That the DetermaIO Gene Expression Test May Predict Response to Immunotherapy in Triple Negative Breast Cancer
GlobeNewswire · 05/13 22:51
Oncocyte Highlights New Data Showing DetermaIO Gene Expression Test May Predict Response IN Immunotherapy In Triple Negative Breast Cancer At ASCO
Oncocyte Corporation (NYSE:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced presentations at the 2020
Benzinga · 05/13 22:08
Edited Transcript of OCX earnings conference call or presentation 12-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 05/13 08:18
Oncocyte Corporation (OCX) CEO Ronald Andrews on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/13 03:41
OncoCyte Corporation Common Stock Q1 EPS $(0.130) Misses $(0.110) Estimate
OncoCyte Corporation Common Stock (AMEX:OCX) reported quarterly losses of $(0.130) per share which missed the analyst consensus estimate of $(0.110) by 18.18 percent. This is a 62.5 percent decrease over losses of
Benzinga · 05/12 20:14
Oncocyte Provides Corporate Update And Reports First Quarter 2020 Financial Results
Announced Final Medicare LCD from Palmetto for DetermaRx™, Potentially Establishing Medicare Coverage for up to 70% of Eligible Early-Stage NSCLC Patients Signed First.
GlobeNewswire · 05/12 20:05
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.
Benzinga · 05/10 19:40
Oncocyte to Report First Quarter 2020 Financial Results on Tuesday, May 12
GlobeNewswire · 05/05 13:00

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About OCX

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.
More

Webull offers kinds of OncoCyte Corp stock information, including AMEX:OCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCX stock news, and many more online research tools to help you make informed decisions.